Accessibility Menu
Halozyme Therapeutics logo

Halozyme Therapeutics(NASDAQ) HALO

Market Cap$11.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+2,382%
5 Year+173%
1 Year+52%
1 Month+35%
$104.86
+1.81%
+1.86Today
After hours$106.25+$1.39 (+1.33%)
Halozyme Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 104.892026-08-18
Halozyme Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.21%USD 102.622026-08-11
1 month+34.8%USD 77.812026-07-17
3 month+52.06%USD 68.982026-05-20
Year to date+55.85%USD 67.302025-12-31
1 year+52.1%USD 68.962025-08-18
3 year+142.46%USD 43.262023-08-18
5 year+172.65%USD 38.472021-08-19
Since inception+2,381.93%USD 4.152004-03-12

Halozyme Therapeutics Financials at a Glance

Market Cap

$11.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.66B

Net Income (TTM)

$413.60M

EPS (TTM)

$3.35

P/E Ratio

31.34

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$104.86

Volume

8

Open

$102.95

Previous Close

$104.89

Daily Range

$102.39 - $105.11

52-Week Range

$61.23 - $105.11

Estimated Earnings Date

Nov 2, 2026

HALO News

Dice spelling ETF on stacks of coins

How to Invest in iShares Russell 2000 ETF (IWM)

Robin Hartill, CFPFeb 27, 2026
Axesome

2 Under-the-Radar Biotech Stocks Set to Boom in 2026

James HalleyJan 24, 2026
mqdefault (67)

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty

Motley Fool YouTubeJan 19, 2026
GettyImages-1473190615

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Josh Kohn-LindquistDec 6, 2025
retirement home assisted living.jpg

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Josh Kohn-LindquistNov 5, 2025
Foolcom-Featured.png

Halozyme (HALO) Q2 EPS Jumps 69%

Motley Fool Markets TeamAug 5, 2025
GettyImages-1126511626

Would Halozyme Make a Good Warren Buffett Stock?

Alex CarchidiApr 4, 2021
GettyImages-1024178290

Are Biotech Stocks a Good Hedge Against Higher Inflation?

Alex CarchidiMar 27, 2021
Page 1

HALO: Motley Fool Moneyball Superscore

81

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. helps people receive medicine through quick skin injections. This makes treatments faster and more comfortable for patients. The company partners with large drug makers to deliver therapy.

How Patients Receive Medicine

  • ENHANZE Technology: Drug delivery platform using a proprietary enzyme to facilitate subcutaneous injections of biologics and fluids.
  • Partnered Products: Royalty-bearing medicines like DARZALEX FASPRO and Phesgo developed with pharmaceutical companies such as Roche and Janssen.
  • XYOSTED: Proprietary auto-injector product used for testosterone replacement therapy in adult males.
  • Hylenex Recombinant: Branded human hyaluronidase injection used to increase the absorption of other injected drugs.

Recent Growth and Partnerships

  • Acquired Elektrofi in November 2025 to add microparticle technology for drug concentration.
  • Signed a global collaboration with GlaxoSmithKline in May 2026 for oncology targets and antibody-drug conjugates.
  • Partnered with Incyte in July 2026 to evaluate new formulations for myeloproliferative neoplasms.
  • Established agreements with Vertex and Oruka in 2026 to utilize Hypercon delivery technology.

Why Halozyme Stands Out

The proprietary enzyme platform converts long intravenous infusions into injections lasting only a few minutes. This technology can provide additional exclusivity and extend the patent life of partner medications.

The Latest Financial Facts

  • Total royalties reached $307.7 million in the second quarter of 2026, up 50% year over year.
  • Net product sales were $129.6 million in the second quarter of 2026, up 59% year over year.
  • The company repurchased 4.8 million shares for $332.8 million during the second quarter of 2026.
  • Operating expenses rose to $193.3 million in the second quarter of 2026, up 57% year over year.
  • Cash, cash equivalents, and marketable securities totaled $231.0 million as of June 30, 2026.

Bottom Line

Halozyme has transitioned from a research firm into a commercial-stage partner for global drug companies. Its focus on drug delivery platforms provides recurring royalty streams from a diverse pharmaceutical portfolio.

AI Generated • Aug 10, 2026

Industry

Biotechnology

Sector

Health Care

Employees

423

CEO

Helen I. Torley, MD

Website

www.halozyme.com

Headquarters

San Diego, CA 92130, US

HALO Financials

Key Financial Metrics (TTM)

Gross Margin

78.18%

Operating Margin

56.77%

Net Income Margin

24.86%

Return on Equity

180.63%

Return on Capital

37.25%

Return on Assets

16.05%

Earnings Yield

3.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

113.50M

Volume

8

Avg. Volume

2.01M

Financials (TTM)

Gross Profit

$1.30B

Operating Income

$944.49M

EBITDA

$714.03M

Operating Cash Flow

$818.60M

Capital Expenditure

-$12.37M

Free Cash Flow

$806.22M

Cash & ST Invst.

$231.00M

Total Debt

$2.15B

Halozyme Therapeutics Performance Analysis

Halozyme Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 660,116,00048.9%
20232023-12-31USD 829,253,00025.6%
20242024-12-31USD 1,015,324,00022.4%
20252025-12-31USD 1,396,611,00037.6%
Halozyme Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.8%
Q42025-12-3127.5%
Q12026-03-31-16.6%
Q22026-06-3027.7%
Halozyme Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.44-47.6%
20232023-12-31USD 2.1046.0%
20242024-12-31USD 3.4363.5%
20252025-12-31USD 2.56-25.5%
Halozyme Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.5%
Q42025-12-31-183.9%
Q12026-03-31201.7%
Q22026-06-3055.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$481.00M

+47.7%

Gross Profit

$401.83M

+53.6%

Gross Margin

83.54%

N/A

Market Cap

$11.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$28.14M

N/A

Employees

423

N/A

Net Income

$229.91M

+39.2%

EBITDA

$320.00M

+39.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$231.00M

-57.9%

Total Debt

$2.15B

+42.2%

Accounts Receivable

$455.83M

+44.1%

Inventory

$137.14M

-24.4%

Long Term Debt

$1.94B

+28.4%

Short Term Debt

$208.97M

N/A

Return on Assets

16.05%

N/A

Return on Invested Capital

42.30%

N/A

Free Cash Flow

$236.72M

+141.2%

Operating Cash Flow

$240.89M

+141.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CORTCorcept Therapeutics Incorporated
$118.10+0.79%
HSICHenry Schein, Inc.
$89.23-0.32%
CYTKCytokinetics, Incorporated
$76.10+0.30%
ABVXAbivax S.A.
$118.94-1.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$17.84-0.24%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.19+0.15%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$129.10-0.15%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.28+0.05%

Questions About HALO

What is the current price of Halozyme Therapeutics?

Halozyme Therapeutics is trading at $104.89 per share.

What is the 52-week range for Halozyme Therapeutics?

Over the past 52 weeks, Halozyme Therapeutics has traded between $61.23 and $105.11.

How much debt does Halozyme Therapeutics have?

As of the most recent reporting period, Halozyme Therapeutics reported total debt of $2.15B.

How much cash does Halozyme Therapeutics have on hand?

Halozyme Therapeutics reported $163.14M in cash and cash equivalents in its most recent financial results.

What is Halozyme Therapeutics’s dividend yield?

Halozyme Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services